

Docket No.: 37998-237524
(PATENT)

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Patent Application of:
Buchacher et al.

Art Unit: Not Yet Assigned

Application No: 10/590,900

Examiner: Not Yet Assigned

Confirmation No:

Filed: August 28, 2006

Atty. Docket No: 37998-237524

For: A METHOD OF PROVIDING A
PURIFIED, VIRUS SAFE ANTIBODY
PREPARATION

Customer No:

26694

PATENT TRADEMARK OFFICE

INFORMATION DISCLOSURE STATEMENT (IDS)

MS Amendment
Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

Dear Sir:

Pursuant to 37 CFR 1.56, 1.97 and 1.98, the attention of the Patent and Trademark Office is hereby directed to the references listed on the attached PTO/SB/08. It is respectfully requested that the information be expressly considered during the prosecution of this application, and that the references be made of record therein and appear among the "References Cited" on any patent to issue therefrom.

This Information Disclosure Statement is filed before the mailing date of a first Office Action on the merits as far as is known to the undersigned (37 CFR 1.97(b)(3)).

Documents BB, BC, CA, CB and CC were cited in an International Search Report issued in the parent PCT application. A copy of the International Search Report is attached. Copies of the documents BB, BC, CA, CB and CC are not being provided since copies are furnished directly by WIPO under an exchange program between the PTO, the EPO and the JPO. If a copy of a cited document is desired, please inform the undersigned and a copy of the missing document will be supplied.

References BA, CD and CE were cited in the European Search Report for the European application. A copy of the European Search Report is attached along with copies of references BA, CD and CE.

A concise explanation of relevance of the items listed on form PTO/SB/08 is in the form of an English language copy of a Search Report from a foreign patent office, issued in a counterpart application, which refers to the relevant portions of the references.

In accordance with 37 CFR 1.97(g), the filing of this Information Disclosure Statement shall not be construed to mean that a search has been made or that no other material information as defined in 37 CFR 1.56(a) exists. In accordance with 37 CFR 1.97(h), the filing of this Information Disclosure Statement shall not be construed to be an admission that any patent, publication or other information referred to therein is "prior art" for this invention unless specifically designated as such.

It is submitted that the Information Disclosure Statement is in compliance with 37 CFR 1.98 and the Examiner is respectfully requested to consider the listed references.

The Director is hereby authorized to charge any deficiency in the fees filed, asserted to be filed or which should have been filed herewith (or with any paper hereafter filed in this application by this firm) to our Deposit Account No. 22-0261, under Order No. 37998-237524.

Dated: February 20, 2007

Respectfully submitted,

By Kavita B. Lepping
Kavita B. Lepping
Registration No.: 54,262
VENABLE LLP
P.O. Box 34385
Washington, DC 20043-9998
(202) 344-4000
(202) 344-8300 (Fax)
Attorney/Agent For Applicant

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449/PTO				Complete if Known	
INFORMATION DISCLOSURE STATEMENT BY APPLICANT <i>(Use as many sheets as necessary)</i>				Application Number	10/590,900
Sheet	1	of	1	Filing Date	August 28, 2006
				First Named Inventor	Andrea Buchacher
				Art Unit	Not Yet Assigned
				Examiner Name	Not Yet Assigned
				Attorney Docket Number	37998-237524

U.S. PATENT DOCUMENTS					
Examiner Initials*	Cite No. ¹	Document Number Number-Kind Code ² (if known)	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear

FOREIGN PATENT DOCUMENTS					
Examiner Initials*	Cite No. ¹	Foreign Patent Document Country Code ³ -Number ⁴ -Kind Code ⁵ (if known)	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
					T ⁶
BA		EP-0 374 625 A	06-27-1990	Miles Inc.	
BB		EP-0 893 450 A1	01-27-1999	Bayer Corporation	
BC		WO-2005/073252	08-11-2005	Suomen Punainen Risti Veripalvelu	

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. ¹Applicant's unique citation designation number (optional). ²See Kinds Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04. ³Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. ⁶Applicant is to place a check mark here if English language Translation is attached.

NON PATENT LITERATURE DOCUMENTS					
Examiner Initials	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.			
	CA	Steinbuch, M. et al., "Isolement de l'immunoglobuline IgG du plasma humain a l'aide de 1'acide caprylique," Rev. Franc. Etudes Clin. et Biol., vol. 14, 1969, pgs. 1054-1058.			
	CB	Habeeb et al., "Preparation of human immunoglobulin by caprylic acid precipitation," Preparative Biochemistry, New York, NY, vol. 14, no. 1, 1984, pgs. 1-17			
	CC	Lundblad, J. L. et al., "Inactivation of Lipid-Enveloped Viruses in Proteins by Caprylate," Vox Sanguinis, S. Karger AG, Basel, CH, vol. 60, no. 2, 1991, pgs. 75-81			
	CD	Lebing, W. et al., "Properties of a new intravenous immunoglobulin (IGIV-C, 10pc) produced by virus inactivation with caprylate and column chromatography," Vox Sanguinis, vol. 84, 2003, pgs. 193-201			
	CE	Trejo, S. R. et al., "Evaluation of virus and prion reduction in a new intravenous immunoglobulin manufacturing process," Vox Sanguinis, vol. 84, 2003, pgs. 176-187			

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹Applicant's unique citation designation number (optional). ²Applicant is to place a check mark here if English language Translation is attached.

Examiner Signature	Date Considered
--------------------	-----------------